N@N

XYTOS Signs Agreement to List on German Stock Exchange

^{Published on 2011-04-28 05:41:11 - Market Wire}
 

CARSON CITY, Nev.--([ BUSINESS WIRE ])--XYTOS, Inc. (the aCompany") (OTC: XYTS) is pleased to announce that after months of preparation, planning, disclosure, and due diligence, XYTOS embarks on the Most Significant Financial Event in the companya™s history.

XYTOS has signed an agreement that will stabilize the companya™s financial future and positively effect the company and the existing shareholders in several ways. The agreement will effectively move XYTOS to an additional public listing, which would now include the Deutsche Boerse Stock Exchange in Germany; one of the most respected Stock Exchanges in the World. The company elected to move in this direction at this time for several reasons. Reasons include European Institutional and Stock Market Support as well as the MOST SIGNIFICANT benefit to the company and the shareholders, which will be the European Based Financial Support for the future of the company. This financial support will give the company the necessary capital to implement the companya™s business model and allow the expansion of XYTOS in the US and Europe.

Although the companya™s technology is unique, XYTOS, like many companies, has lacked the funding necessary to fully implement the business plan. This agreement and direction will set a firm foundation and allow the companya™s Medical and Research Doctors to continue and expand their work.

Additionally XYTOS has worked hard to avoid dilution to the existing shareholders; with this said, the company has not issued a free trading share since the original registration more than a decade ago. The company has had to issue restricted non-tradable shares to secure specific Bio-Medical Technologies, which brought the companya™s current outstanding shares to 31,268,000. In an attempt to continue our efforts to avoid unnecessary dilution to our existing shareholders, unique aspects of the agreement will allow for funding without dilution to our existing shareholders.

Tim Cook, Chairman and CEO of XYTOS, Inc., commented, aIn todaya™s economy it has been difficult for many companies to grow, we have worked hard to put XYTOS in a position to secure the necessary funding to move the company forward. With a large majority of our KEY Supporters based in Europe as well as a number of our Doctors and Medical Management, it was a natural direction that the company was planning to take. The timing of the Deutsche Boerse Listing now is being done to bring XYTOS in line with the requirements necessary to secure the European Funds that have been structured." Details of the agreement will be disclosed in upcoming new releases.

XYTOS, working at the forefront of the aScience of Medicine," is a Bio-Medical Technologies Company concentrating on the research, development, and introduction of Next Generation Medicine and Medical Procedures in the areas of Stem Cell Therapies, Tissue Engineering, Cellular Medicine, and Cancer.

On behalf of the Board of Directors of: XYTOS Inc.
Tim Cook, CEO (Contact: [ info@xytos.com ]) Telephone: 702-421-5206